{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Rare Kidney Disease Show","title":"Evolving Management of FSGS: Proteinuria and Clinical Data with Drs. Daniel Gale and Gaia Coppock","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/2405b5bd\"></iframe>","width":"100%","height":180,"duration":1716,"description":"Welcome to Travere Therapeutics’ Rare Kidney Disease Show podcast, where rare kidney disease gets a spotlight. Host Dr. Chris Gisler, Senior Medical Director at Travere Therapeutics, is joined by Dr. Daniel Gale and Dr. Gaia Coppock for a practical and evidence driven conversation on FSGS, proteinuria, and what recent evidence means for clinical decision-making.\nIn this episode, Dr. Gaia Coppock reflects on how the heterogeneous nature of focal segmental glomerular sclerosis (FSGS) has historically been challenging for clinicians and highlights we are working towards a new era of research, diagnosis, and therapeutics. From there, the discussion focuses on FSGS as a podocytopathy, outlining different triggering events that converge on podocyte injury and shared downstream pathways. Dr. Daniel Gale goes on to discuss how RaDaR, PARASOL, and other real-world datasets have helped clarify the relationship between proteinuria remission, and long-term kidney outcomes.\nThe conversation also explores the clinical implications of the Phase 3 DUPLEX study. Dr. Coppock reviews the study design and key findings, including rapid and sustained reductions in proteinuria, data on complete remission, safety profiles, and the challenges of interpreting estimated glomerular filtration rate (eGFR) slope in a complex and heterogeneous condition like FSGS. \nTogether, experts reflect on where FSGS care is heading, underscoring the importance of targeting lower proteinuria thresholds, improving diagnostic precision, and adopting multi-targeted approaches.\nSpeakers:\nDr. Chris Gisler is a medical director at Travere Therapeutics and an adult Nephrologist\nDr. Daniel Gale, MBBS, PhD (Professor of Nephrology, University College London. Director, RaDaR/Rare Renal Registry)\nDr. Gaia Coppock, MD (Assistant Professor of Clinical Medicine, Renal-Electrolyte and Hypertension. University of Pennsylvania/Penn Medicine)\nKey Takeaways:\nFSGS is a heterogeneous pattern of injury, not a single condition....","thumbnail_url":"https://img.transistorcdn.com/jM272MCibzIZiqQw59pnA3nZivqEzxd_x4uyrh-4f5Q/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzQ5NjEwLzE3MDc1/MDY4NzctYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}